BioSante rises on FDA OK of male testosterone gel
This article was originally published in Scrip
Shares of BioSante Pharmaceuticals ascended as high as 62% on 15 February on word that the US FDA approved Bio-T-Gel, a testosterone gel the firm has licensed to Teva's US unit, as a treatment for male hypogonadism, or low levels of testosterone, a condition that affects up to five million men over 39 years and is characterized by impotence, a lack of sex drive, decreased energy, increased body fat, muscle weakness and osteoporosis.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.